2x Blend Ipamorelin / CJC-1295 (No DAC) - {12mg Ipamorelin, 6 mg CJC-1295 (No Dac)

Log in to view pricing Apply for provider account
2x Blend Ipamorelin / CJC-1295 (No DAC) - {12mg Ipamorelin, 6 mg CJC-1295 (No Dac)
Availability:
In Stock

Product Overview

GH Secretagogue Blend

A 1:1 blend of CJC-1295 No Drug Affinity Complex (No DAC) (5mg) and Ipamorelin (5mg) is designed to optimize endogenous growth hormone (GH) release, with the goal of promoting muscle growth, fat loss, and enhanced tissue repair.

CJC-1295 No DAC is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary to increase pulsatile GH secretion and insulin-like growth factor I (IGF-I) production. Subcutaneous administration of CJC-1295 in healthy adults results in sustained, dose-dependent increases in plasma GH (2- to 10-fold) and IGF-I (1.5- to 3-fold) for up to 6–11 days, with preserved physiological GH pulsatility and a favorable safety profile. These effects are associated with increased lean body mass, reduced adiposity, and improved protein synthesis in both preclinical and clinical studies.[1][2][3][4]

Ipamorelin is a selective growth hormone secretagogue (GHS) that acts via the ghrelin receptor (GHS-R1a) to stimulate GH release from the pituitary, with minimal impact on ACTH or cortisol levels, even at supraphysiologic doses. Ipamorelin produces rapid, dose-dependent, and transient increases in circulating GH, with a peak at approximately 40 minutes post-infusion and a terminal half-life of about 2 hours. The GH-releasing effect is episodic and returns to baseline within a few hours, with no evidence of prolonged or inappropriate GH secretion. Ipamorelin’s selectivity for GH release and lack of significant ACTH/cortisol stimulation make it a promising candidate for clinical development in conditions requiring GH stimulation.[5][6]

The combination of CJC-1295 No DAC and Ipamorelin is hypothesized to provide synergistic stimulation of the GH/IGF-I axis, leveraging the sustained, physiologic GH release of CJC-1295 with the rapid, selective GH pulse induced by Ipamorelin. This dual approach may optimize both basal and pulsatile GH secretion, supporting muscle hypertrophy, fat loss, and tissue repair. GH secretagogues have demonstrated efficacy in increasing lean body mass, reducing fat mass, and improving recovery in preclinical and early clinical studies, with preserved feedback regulation and a low risk of adverse effects compared to exogenous GH administration.[1][5][2][4][7][3][6][8][9]

In summary, a 1:1 blend of CJC-1295 No DAC (5mg) and Ipamorelin (5mg) is designed to optimize endogenous GH release, promote muscle growth, support fat loss, and enhance tissue repair, with a mechanistic and clinical rationale supported by the current medical literature.[1][5][2][4][7][3][6][8][9]

References

  1. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-releasing Hormone, in Healthy Adults. Teichman SL, Neale A, Lawrence B, et al. The Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536.
  2. Pulsatile Secretion of Growth Hormone (GH) Persists During Continuous Stimulation by CJC-1295, a Long-Acting GH-releasing Hormone Analog. Ionescu M, Frohman LA. The Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-7. doi:10.1210/jc.2006-1702.
  3. Activation of the GH/IGF-1 Axis by CJC-1295, a Long-Acting GHRH Analog, Results in Serum Protein Profile Changes in Normal Adult Subjects. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society. 2009;19(6):471-7. doi:10.1016/j.ghir.2009.03.001.
  4. Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists. Schally AV, Zhang X, Cai R, et al. Endocrinology. 2019;160(7):1600-1612. doi:10.1210/en.2019-00111.
  5. Ipamorelin, the First Selective Growth Hormone Secretagogue. Raun K, Hansen BS, Johansen NL, et al. European Journal of Endocrinology. 1998;139(5):552-61. doi:10.1530/eje.0.1390552.
  6. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmaceutical Research. 1999;16(9):1412-6. doi:10.1023/a:1018955126402.
  7. Growth Hormone Secretagogues and the Regulation of Calcium Signaling in Muscle. Bresciani E, Rizzi L, Coco S, et al. International Journal of Molecular Sciences. 2019;20(18):E4361. doi:10.3390/ijms20184361.
  8. Potential Applications of GH Secretagogs in the Evaluation and Treatment of the Age-Related Decline in Growth Hormone Secretion. Merriam GR, Buchner DM, Prinz PN, Schwartz RS, Vitiello MV. Endocrine. 1997;7(1):49-52. doi:10.1007/BF02778062.
  9. Growth Hormone-Releasing Peptides and Their Analogs. Camanni F, Ghigo E, Arvat E. Frontiers in Neuroendocrinology. 1998;19(1):47-72. doi:10.1006/frne.1997.0158.

All information provided is for research purposes only.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.